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1 Introduction 
Cardiovascular diseases (CVDs) are worldwide medical and public health 
problems that together constitute the leading cause of death in the Western 
world. The majority of CVDs are attributable to atherosclerosis, a disease 
associated with inflammatory events and increased oxidative stress (LIoyd 
Jones, 2009).  
 
A number of studies revealed an inverse correlation of High density lipoprotein 
(HDL) cholesterol (C) plasma levels with cardiovascular risks (for recent reviews 
see Von Eckardstein 2010; Lewington, 2007). HDL exhibits potentially anti-
atherogenic properties attributed to its ability to participate in a process termed 
reverse cholesterol transport (RCT). In this scenario HDL transports cellular 
cholesterol from peripheral tissues to the liver and intestine for excretion in the 
bile and feces (Tall, 2008). The scavenger receptor class B type I (SR-BI) 
mediates the last step in RCT, the delivery of HDL cholesteryl esters (CE) to the 
liver, mainly by selective CE uptake (Krieger, 1999). 
 
It has been reported that HDL looses its cardioprotective properties through 
oxidative modifications generating dysfunctional HDL. ApoA-1, the most 
abundant protein of HDL, is assumed to be the major target for oxidative 
modifications, indicated by reactive oxygen species (ROS) and 
myeloperoxidase, both present in atherosclerotic lesions as a response to 
inflammatory processes in the progression of atherosclerosis (Shao, 2006 & 
2010). The underlying mechanisms remain poorly understood, but it is assumed 
that dysfunctional HDL may result in different cholesterol transfer capacities and 
alterations in RCT. Moreover, SR-BI may be involved in the binding of modified 
HDL (Marsche, 2002). 
The objectives of this diploma thesis were to characterize whether oxidative 
modifications of HDL influence cholesterol efflux from mammalian cells. 
Furthermore, we attempted to analyze if these modifications alter cellular 
binding and uptake compared to native HDL. 
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2 Literature Overview 
2.1 Atherosclerosis 
2.1.1 Epidemiology 
Cardiovascular diseases (CVD) are the leading cause of death of middle-aged 
and elderly people in the western world. Atherosclerosis is the underlying cause 
for the development of CVD. In the USA about 80 million people (or 36% of the 
whole population) obtain existing CVD; 12 million of these individuals in the 
USA are affected by atherosclerosis with a tendency to rise. Similar trends can 
be observed in Europe (LIoyd Jones, 2009; Cooke, 2010).  
Efficacious prevention of cardiovascular diseases includes the treatment of the 
most important risk factors such as cigarette smoking, obesity, diabetes and 
elevated cholesterol levels, especially increased LDL-cholesterol levels 
(Tamada, 2010). For effective cardiovascular prevention the detection and 
recognition of early stages of atherosclerosis is very important. Additionally, the 
role of fibrinogen and highly sensitive C-reactive protein (hs-CRP), to serve as 
new markers in the early detection of atherosclerosis, is discussed (Corrado, 
2010). 
2.1.2 Pathogenesis 
Atherosclerosis is an inflammatory disease, characterized by endothelial 
dysfunction, vascular inflammation and excess cholesterol within the intima of 
the vessel wall. The development of atherosclerotic lesions is the initial step in 
the pathogenesis of atherosclerosis (Libby, 2009). 
 
Functional cell-monolayers within the artery exhibit homeostatic endothelial 
regulation mechanisms to protect against detrimental effects which can damage 
them. For example, healthy vascular endothelial cells combat thrombosis, 
express enzymes, such as superoxide dismutase, to protect against reactive 
oxygen species and produce vasodilator molecules to resist blood flow.  
Exposed to proatherogenic factors, namely increased cholesterol levels, 
modified lipoproteins, such as oxidized LDL, or disturbed blood flow, the cells of 
an artery became dysfunctional (Libby, 2010). As a response endothelial cells 
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express leukocyte adhesion molecules, such as vascular cell adhesion 
molecule-1 (VCAM-1) and leukocytes then enter the endothelial barrier. This is 
followed by attachment of other blood cells and cytokine release of the intima 
(Goldberg, 2009). This process is enhanced by monocytical proliferation 
mediated by monocyte-colony stimulating factor (M-CSF). Macrophages 
internalize intracellular cholesterol derived from lipoproteins within the 
developed plaques in the artery (Hansson, 2005). This results in foam cell 
formation and is a further characteristic in the progression of atherosclerosis 
and impacts early stages of atherogenesis as well as late lesion development 
(Boyle, 2005). 
Monocyte recruitment is aided by endothelial expression of inflammatory signals 
and activation in the cytokine cascade. The cytokine cascade activation leads to 
an increased release of interleukin-6 (IL-6), interleukin-1 (IL-1), tumor necrosis 
factor α (TNFα), C-reactive protein (CRP) and some more (Goldberg, 2009).  
Figure 1: Progression of Atherosclerosis (Rader, 2008) 
The development of fatty streaks to occlusions is shown. For further description, 
see text. 
 
 
Atherosclerosis occurs at sites of an artery where laminar flow is disrupted. A 
lesion is initiated as a fatty streak (Fig. 1a), can develop into an intermediate 
lesion (Fig. 1b), further progress into a lesion that is vulnerable to rupture (Fig. 
1c) and, finally, into an advanced obstructive lesion (Fig. 1d). The fatty streaks 
are thought to be the initial status a lesion leading to the development of 
complex atherosclerosis. Plaque, within an artery can rupture, resulting in the 
exposure of thrombogenic material and the formation of a thrombus in the 
lumen. Finally, the developed thrombus can narrow or completely block the 
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artery, leading to myocardial infarction, stroke and peripheral artery occlusive 
disease (PAOD; Rader, 2008).  
Inflammatory events and increased cell immune response potentially account 
for the development of atherosclerosis and in general for cardiovascular 
diseases (Corrado, 2010). As mentioned above, lipoproteins are critically 
involved in these processes. 
2.2 Lipoproteins 
2.2.1 Lipoprotein Metabolism 
Lipoproteins transport fatty lipids in the blood. 
Lipoproteins are classified according to their specific densities and molecular 
sizes into high density lipoprotein (HDL), low density lipoprotein (LDL), 
intermediate density lipoprotein (IDL), very low density lipoprotein (VLDL) and 
chylomicrons. Besides, these classes of lipoproteins differ in physiological 
function, lipid composition and apolipoprotein content (Olofsson, 2009). 
Lipoproteins consist of a core of neutral lipids, such as triglycerides and 
cholesteryl esters, surrounded by an amphiphilic shell of phospholipids, free 
cholesterol and proteins, so-called apolipoproteins (Fig. 2; Wasan, 2008). 
Figure 2 Composition of Lipoproteins (Wasan, 2008) 
Lipoproteins consist of a core of neutral lipids, surrounded by an amphiphilic 
shell of phospholipids, free cholesterol and proteins, so-called apolipoproteins. 
 
The lipoprotein metabolism follows two main pathways: the exogenous 
pathway, where lipoproteins are mainly composed of dietary lipids and the 
endogenous pathway, where lipoproteins originate in the liver (Wasan, 2008).  
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After oral ingestion and digestion of food, dietary fat is absorbed by the intestine 
and packaged into chylomicrons (Fig. 3); in this stage they are termed nascent 
chylomicrons and contain apoB-48. Chylomicrons enter the circulation and 
acquire apoC-2 and apoE from HDL. This process leads to the maturation of 
nascent chylomicrons in the blood. Chylomicrons are transported by blood to 
muscle and adipose tissues and within these tissues the enzyme lipoprotein 
lipase (LPL) breaks down chylomicrons. LPL catalyzes the hydrolysis of 
triglycerides in chylomicrons to transfer fatty acids to tissues (Daniels, 2009). 
Additionally, this process generates non-esterified fatty acids in plasma and 
remodels chylomicrons into chylomicron remnants (CR). CR are taken up by the 
liver and CR lipids are hydrolyzed for VLDL synthesis (Rigotti, 2003). Within 
hepatocytes lipids of CR are used for apoB lipidation, which is then secreted as 
VLDL. In the circulation VLDL exchanges apoC-2 and apoE with HDL. VLDLs 
deliver free fatty acids to adipose and muscle tissue and activate LPL. Like 
chylomicrons, VLDL triglycerides are hydrolyzed by LPL to rise smaller 
intermediate density lipoproteins (IDL) particles. IDL are either removed from 
circulation by hepatic endocytosis, which includes receptors, such as the LDLR, 
or, through the action of cholesteryl ester transfer protein (CETP) and hepatic 
lipase, further converted to low density lipoproteins (LDL; Maxfield, 2002). LDLs 
are the major carriers of cholesterol and cholesteryl esters in humans. LDL is 
removed from circulation by LDL receptor mediated endocytosis, a process in 
which LDL is internalized and delivered to lysosomes for degradation (Brown, 
1986). 
Figure 3. Lipoprotein Metabolism (Rader, 2008) 
Lipoprotein metabolism has a key role in atherogenesis. It involves the transport 
of lipids, particularly cholesterol and triglycerides, in the blood mediated by 
lipoproteins. For further description, see text. 
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2.2.2 High Density Lipoprotein (HDL) 
Anti-Atherogenity of HDL 
There is evidence for an inverse association between plasma high density 
lipoprotein cholesterol (HDL-C) concentrations and the risk of cardiovascular 
disease. HDL is thought to protect against the future development of CVD 
related to mechanisms that have a potentially anti-inflammatory capacity 
(Cooney, 2009).  
The major antiatherogenic function of HDL is associated with its ability to 
mediate cholesterol efflux from cells in a process termed reverse cholesterol 
transport (Rothblat, 2010). A key-role of HDL in vascular protection is the 
removal of cholesterol from lipid-laden macrophages within the vessel walls 
(Vergeer, 2010). 
HDL Composition 
High density lipoprotein is the smallest lipoprotein with a density in the range of 
1,063-1,21 g/ml and contains the least amount of lipids (Rader, 2008). The 
shape of HDL particles ranges from discoidal to spherical with different 
subclasses of HDLs, which vary in lipid and protein composition, density and 
electrophoretic mobility (Lund-Katz, 2003). 
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On the basis of electrophoretic mobility, HDL can be separated into two main 
subgroups, namely α-HDL and β-HDL. In plasma, most HDL can be found as α-
HDL whereas β-HDL represents only approximately 5-15% (Rothblat, 2010). 
The major component of both subclasses of HDL is the apoA-1 protein. ApoA-1 
is supposed to activate the enzyme lecithin:cholesterol acetyl transferase 
(LCAT) which is responsible for the esterification of plasma cholesterol (Rader, 
2009). 
HDL is secreted by the liver and intestine in form of nascent HDL, containing 
apoA-1 and free cholesterol (FC). Nascent HDL interacts with peripheral cells, 
such as macrophages, to remove excess free cholesterol (Liu, 2003; Duong, 
2006). This process is mediated by the ATP-binding cassette A1 (ABCA 1) 
gene. Nascent HDL is converted into mature HDL (Fig. 4), which has a high 
amount of cholesteryl esters, which are synthesized from free cholesterol and 
fatty acids by the enzyme LCAT (Duong, 2006). 
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Figure 4. Maturation of High Density Lipoprotein  
(http://lipidlibrary.aocs.org/Lipids/lipoprot/index.htm; 18.06.2010) 
Nascent HDL is converted into mature HDL, mediated by the enzyme lecithin 
cholesterol acetyl transferase (LCAT) which requires apoA-1 for activation. 
 
 
2.2.3 Oxidized Phospholipids and Dysfunctional HDL 
Oxidation of Phospholipids is one of the hallmarks in the pathogenesis of 
atherosclerosis. Oxidized phospholipids (oxPLs) are associated with 
lipoproteins in the circulation and, besides activating inflammatory signals, 
oxidized phospholipids can inhibit the uptake of lipids associated with HDL. 
Additionally, the cholesterol transport mediated by HDL can be impeded by 
oxPL (Fu, 2008). The levels of oxPL in circulation increase in chronic and acute 
pathologic events, namely hyperlipidemia and atherosclerosis (Fu, 2008; 
Deigner, 2008).  
 
Phospholipids associated with lipoproteins or cell membranes are the major 
source for oxPLs. oxPLs are generated by lipid peroxidation induced by an 
enhanced generation of reactive oxygen species (ROS) or decreased 
antioxidant defense (Fu, 2008). Once they are oxidatively modified they 
undergo a number of pathways inducing inflammatory signals, such as IL-8 and 
others, and cytotoxic events. Phospholipids containing polyunsaturated fatty 
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acids are particularly susceptible for modification by ROS (Deigner, 2008). 
Important biologically active PLs, generated by oxidation processes, include 1-
palmitoyl-2-(5-oxovaleroycl)-sn-glycero-phosphocholine (POVPC), 1-palmitoyl-
2-glutaroyl-sn-glycero-phosphocholine (PGPC) and 1-palmitoyl-2-(5,6-epoxy-
cyclopentenone)-sn-glycero-3-phosphocholine (PECPC). POVPCs and PGPCs 
are generated through oxidatively induced truncation of the sn-2 residues of 
fatty acids, whereas PECPC development is based on the addition of oxygen 
atoms to the sn-2 fatty acid residues (Fu, 2008). 
oxPLs associated with HDL serve as ligands for CD36 as well as SR-BI. 
Studies demonstrated that oxPLs prevent HDL binding to SR-BI because of the 
close proximity of the structure of both receptors (Gao, 2010). The interaction 
between oxPLs and the SR-BI receptor may indicate an inhibition of HDL 
derived lipids, which leads to indifferent cholesterol transfer capacities. 
Moreover, selective uptake of cholesteryl esters seems to be inhibited by 
increased levels of oxPLs (Ashraf, 2008). 
In addition to oxPLs, modifications of apoA-1, the major protein of HDL, may 
also implicate oxidative generation of dysfunctional HDL attributed to alterations 
in lipid transfer and selective cholesteryl ester (CE) uptake derived from HDL 
(Ashraf, 2008).  
Reactive carbonyls, such as malondialdehyde (MDA), develop due to lipid 
peroxidation and have been found in atherosclerotic lesions in vivo. ApoA-1 
seems to serve as a potential target for modifications by reactive carbonyls 
(Shao, 2010). 
Especially lysine residues within apoA-1 underlie changes in their chemical 
structure. Modification of apoA-1 by MDA forms cross-links between different 
lysine residues and this may affect the conformational adaptability of apoA-1 
(Shao, 2006). This results in a reduced ability of apoA-1 to interfere with ABCA1 
(Fig. 5), a major receptor for apoA-1 associated lipids in reverse cholesterol 
transport (RCT). Furthermore, MDA modified apoA-1 within reconstituted HDL 
looses its ability to activate lecithin:cholesterol acyltransferase (LCAT), an 
important enzyme in RCT and HDL maturation (Shao, 2010).  
MDA mediated oxidation also severely limited the ability of apoA-1 to exchange 
between HDL-associated lipid-free and lipid-poor states, a keyrole mechanism 
in the progression of atherosclerosis (Cavigiolio, 2010). Beyond these findings, 
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it was reported that dysfunctional HDL is associated with decreased 
paraoxonase-1 (PON1) activity. PON1 is an esterase that is found in circulation 
bound to HDL and it is thought to degrade oxidized phospholipids in lipoproteins 
(Marsillach, 2010). Alterations in PON1 levels in circulation have been found 
associated with diseases involving oxidative stress, such as atherosclerosis 
(Mackness, 1995). 
Figure 5. HDL modified with hypochlorite is able to interfere with RCT 
(Malle, 2005).  
Overview of the HDL metabolism: the dashed lines show possible interaction 
pathways for HOCl modified HDL in reverse cholesterol transport. 
 
2.3 Cellular Cholesterol Homeostasis  
Cholesterol is an essential component of the plasma membrane of mammalian 
cells. It maintains the barrier function between cells and environment, 
modulates fluidity, and is also the precursor for steroid hormone synthesis and 
bile acids. The cellular supply of cholesterol can be maintained by three defined 
mechanisms: synthesis of cholesterol, uptake and cholesterol efflux. The 
homeostasis of cellular cholesterol content is essential for optimal cell viability 
and function (Rader, 2008). 
Cholesterol is synthesized in the endoplasmatic reticulum (ER) under the 
control of the enzyme acetyl-CoA by 3-hydroxy-3-methylglutaryl coenzyme A 
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(HMG-CoA) reductase. Additionally to the biosynthesis, cholesterol levels are 
controlled by endocytosis of lipoproteins. 
 
Excess cholesterol derived from lipoproteins is stored as cholesteryl esters 
within lipid droplets. The storage of cholesterol as cholesteryl esters is 
controlled by the esterifying enzyme acyl CoA:cholesterol acyltransferase 
(ACAT). Cholesteryl esters from apo-B/E containing lipoproteins are taken up 
via the LDL receptor (LDLR). After endocytosis cholesteryl esters are 
hydrolyzed in endosomes and lysosomes by acidic cholesteryl ester hydrolases 
(Wang, 2005). Cholesterol levels and intracellular cholesterol content are 
regulated by the LDL receptor and HMG-CoA reductase (Brown, 1986). The 
transcription levels of the LDLR and HMG-CoA genes are controlled by 
transcription factors including sterol responsive element binding proteins 
(SREBPs). SREBPs are sensors for cholesterol and regulate cholesterol 
homeostasis by controlling de novo synthesis via HMG-CoA and cholesterol 
uptake via the LDLR. Additionally, the nuclear transcription factors liver X 
receptors (LXRs) regulate the expression of ABCA1 and ABCG1, both of them 
involved in cholesterol efflux from cells (Brown, 1986; Eberle, 2004). 
2.3.1 Reverse Cholesterol Transport and Cholesterol Efflux from Cells 
Reverse cholesterol transport (RCT) is a process described to remove excess 
cholesterol from peripheral tissues for disposal by the liver and the bile. 
Peripheral tissues dispose cholesterol by effluxing to extracellular receptors, 
such as lipoproteins. ApoA-1, the mayor protein of HDL, serves as an acceptor 
for cellular cholesterol in its lipid-poor form (Rader, 2008). 
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Cholesterol efflux follows different pathways: 
Efflux to lipid-poor apolipoproteins, such as apoA-1; this pathway is mainly 
mediated by ABCA1. 
Efflux to mature HDL particles is promoted by ABCG1 and scavenger receptor 
class B type I (SR-BI; Rader, 2008). 
 
Lipid -poor apoA-1, secreted from the liver, acquires free cholesterol, released 
from macrophages or other cells from peripheral tissues, via the ABCA1 
pathway. Afterwards, free cholesterol, associated with nascent HDL, is 
converted into cholesteryl esters by lecithin:cholesterol acyltransferase (LCAT). 
In this process HDL is remodeled to mature HDL containing cholesteryl esters. 
Mature HDL transports its cholesterol to the liver for disposal and bile-secretion 
or steroid hormone synthesis. The transport of HDL-CE to the liver follows two 
main pathways. Selective uptake of HDL-CE mediated by SR-BI or by 
triglyceride-rich lipoproteins, such as LDL and VLDL, via the LDL receptor 
(LDLR; Tall, 2008; Brown, 1986). Selective uptake is considered as a non-
endocytotic mechanism where lipoproteins bind with high affinity to SR-BI for 
lipid transfer. Afterwards, lipid-depleted lipoproteins are released from cells and 
re-enter circulation. Additionally, CE derived from HDL is transferred to LDL and 
VLDL by CE transfer protein (CETP) and subsequently removed from the 
circulation by endocytosis via the LDL-receptor (LDLR; Fluiter, 1997; Rhainds, 
2002). 
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2.3.2 Important Receptors involved in Reverse Cholesterol Transport 
and Cholesterol Efflux from Cells  
Scavenger Receptor class B type I (SR-BI) 
SR-BI is described as a multi-ligand receptor, localized on the surface of cells, 
and belongs to the scavenger receptor CD36 superfamily. It is a 509-amino 
acid, 82 kDa glycoprotein containing a large extracellular domain and two 
transmembrane domains with short cytoplasmic amino- and carboxyl-terminal 
tails (for a review see: Murphy, 2005). SR-BI is expressed in tissues with crucial 
roles in cholesterol metabolism, namely the liver and steroidogenic tissues with 
the highest mass of SR-BI protein found in the liver, specifically, in parenchymal 
hepatic cells. These tissues exhibit the highest levels of selective uptake of 
cholesteryl esters derived from HDL (Krieger, 1999; Fluiter, 1998). 
SR-BI was first identified as a receptor for oxidized LDL, acetylated LDL and 
native LDL (Krieger, 1994). Later, Acton et al. showed that SR-BI mediates 
selective uptake of HDL derived cholesteryl esters (CE) (Acton, 1996). 
Moreover, SR-BI is reported to serve as a receptor for oxidized HDL, for 
example, after oxidation by myeloperoxidase-generated hypochlorite (Marsche, 
2002). SR-BI mediates bidirectional exchange of lipids, which is implicated as 
selective uptake of CE and FC from lipoproteins and efflux of FC to lipoproteins 
(Stangl, 1998; Swarnakar, 1998). Selective uptake of CE supplies cholesterol to 
liver and steroidogenic tissues and further for secretion by bile and for steroid 
hormone synthesis (Rhainds, 2004). In this process SR-BI promotes hepatic 
uptake of HDL (both esterified and unesterified) considered as a non-
endocytotic mechanism, contrary to the LDLR mediated endocytosis. 
Lipoproteins bind with high affinity to SR-BI and after lipid transfer, lipid-
depleted lipoproteins are released from cells and re-enters circulation. Multiple 
studies utilizing SR-BI knock out mice models indicate that HDL-CE selective 
uptake is diminished compared to wild type mice. These results further suggest 
an important role of SR-BI in reverse cholesterol transport (Rigotti, 2003). 
In addition to selective uptake, HDL holo-particle uptake was shown to be 
mediated by SR-BI. This pathway, which includes HDL endocytosis and 
resecretion, is discussed as an alternative path to maintain cellular cholesterol 
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homeostasis in cases where cholesterol metabolism is disturbed (Pagler 2006 & 
2007; Röhrl 2010).  
ATP- binding cassette (ABC) transporters ABCA1 and ABCG1 
ABC transporters are transmembrane proteins that utilize adenosine 
triphosphate (ATP) hydrolysis to transport various substrates, such as lipids and 
sterols, across extra- and intracellular membranes (Tall, 2008).  
The expression of ABCA1 and ABCG1 is mainly regulated by liver X receptors 
(LXRs), ligand-activated transcription factors that belong to the nuclear receptor 
super family. In this process LXRs renders mutual compensation in the activities 
of both receptors (Tall, 2008). ABCA1 promotes cholesterol efflux to lipid-poor 
apoA 1 in a process that involves the direct binding of apoA-1 to the transporter 
(Oram, 2000). In contrast, ABCG1 promotes cholesterol efflux to a variety of 
lipoprotein particles, such as HDL, LDL and phospholipid-vesicles, but does not 
seem to bind lipoprotein particles (Wang, 2006).  
To point out the importance of ABCA1, people with mutations or deficiency of 
ABCA1 suffer from low HDL cholesterol levels and increased accumulation of 
cholesterol in various tissues. This syndrome is termed Tangier disease (Rust, 
1999). Furthermore, a set of studies suggest major roles of ABCA1 and ABCG1 
in cholesterol efflux from macrophages to HDL. For example, mice with a 
combined deficiency of both receptors revealed an increase of cholesterol 
accumulation in form of cholesteryl esters as well as foam cell accumulation in 
various organs compared to wild type mice (Yvan-Charvet, 2007). Up-regulation 
of ABCA1 and ABCG1 transporters is thought to be a beneficial target for 
therapeutic strategies in cardiovascular diseases (Trogan, 2006). 
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3 Material and Methods 
3.1 Tissue Culture 
3.1.1 Cell lines  
ldlA7-SRBI (Acton, 1996; Stangl, 1998): This cell line is a Chinese Hamster 
Ovarian (CHO) cell line that lacks LDL receptor activity (Kingsley,1984). 
Furthermore, ldlA7-SRBI cells overexpress the SR-BI receptor. ldlA7-SRBI cells 
were maintained in DHG medium, a 1:1 mixture of Dulbecco’s minimal essential 
medium (DMEM) and Ham’s F-12 medium (Gibco). The DHG medium is 
supplemented with 1% penicillin (100 units/ml)/streptomycin (100 mg/ml; 
pen/strep) and 5% fetal calf serum (FCS). 
 
HepG2 (HB-8065; LGC Standards): These cells are human hepato-carcinoma 
cells and the cell line is a widely used model for human hepatocytes. 
HepG2 cells were maintained in minimal essential medium (MEM; Gibco) 
supplemented with 1% pen/strep, 10% FCS, 1% non-essential amino acids 
(AA) and 1% L-glutamine. 
 
THP-1 (TIB-202; LGC Standards): THP-1 cells are monocytic leukemia cells. It 
is a human monocytic cell line widely used to study foam cell formation in the 
development of atherosclerosis. The monocytes can be differentiated into 
macrophages by stimulation with phorbol esters such as PMA. THP-1 cells 
were maintained in Roswell Park Memorial Institute (RPMI; PAA Laboratories) 
medium supplemented with 10% FCS, 1% pen/strep and 1% L-glutamine. 
 
THP-1 differentiation 
 
Reagents: 
810 µM Phorbol-12-myristat,13-acetat, (stock solution), PMA (Sigma) 
THP-1 cells, seeded at a concentration of 5*105 cells/well in a 24-well plate, 
were differentiated in RPMI medium (supplemented with 10% FCS, 1% 
pen/strep and 1% L-glutamine) containing 160 nM PMA for 3 days. 
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3.2 Bradford protein assay (Bradford, 1976) 
Reagents:  
Bradford protein assay (BioRad Laboratories) 
Albumin, bovine serum, BSA; (Sigma-Aldrich) 
 
The Bradford assay is used to measure protein concentrations of cell lysates as 
well as lipoproteins. The method is based on the different absorption rates of 
Coomassie brilliant blue. Proteins bind to the red cationic form of Coomassie 
and by binding the protein-Coomassie-complex turns into the anionic form with 
an absorbance at 595 nm. This absorption is measured by photometry. For 
every assay a standard curve with several dilutions of BSA standard protein (c 
= 1 mg/ml) was prepared and measured together with the samples.  
In micro titer plates 0, 1, 2, 5 or 10 µg BSA were mixed with 20 µl Bradford 
reagent and filled to a volume of 100 µl with distilled water. Similarly, 10-20 µl 
samples (depending on the expected concentration) were combined with the 
Bradford reagent and distilled water to obtain a final volume of 100 µl per well. 
Afterwards the absorption was measured spectrophotometrically at 595 nm 
using a micro plate reader (Bio-Rad, Model 550). 
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3.3 Lipoprotein Preparation 
Reagents:  
Potassium bromide, KBr (Merck)  
Dialysis buffer (10x) 
15 M NaCl 
0,5 M EDTA 
pH 7,4 
 
Human plasma was collected from healthy, young, male and female, normal-
lipidemic volunteers after an overnight fasting period. After blood sample 
collection, the anti-coagulant EDTA (2 ml 0,18 M EDTA per 50 ml blood sample) 
was added the blood and centrifuged at 3000 RPM for 20 minutes in an 
Eppendorf centrifuge to obtain plasma. The supernatant was re-centrifuged (at 
3000 RPM for 20 minutes) to remove all red blood cells. 
The density (D) of the plasma was adjusted to the corresponding specific 
densities of the lipoproteins with potassium bromide (KBr) to get the lipoprotein 
fraction. 
 
DPlasma = 1,006; DVLDL = 1,019; DLDL = 1,063; DHDL = 1,210 [g/ml] 
 
The following formula was used to calculate the amount of potassium bromide 
(KBr) needed to adjust the density: 
 
g KBr = Volume sample (ml) * (final density – initial density) 
1- (0,312 * final density) 
 
First, plasma was adjusted to the density of VLDL (1,019 g/ml) by KBr. 
Afterwards ultracentrifuge-tubes were filled with the plasma and centrifuged at 
51 kRPM at 4°C for 20 h in a Beckmann ultracentrifuge (using the 55.2 rotor). 
The VLDL-containing plasma was removed, and the bottom fraction was 
adjusted to the density of LDL (1,063 g/ml), followed by another 
ultracentrifugation step and LDL removal. Finally, the remaining plasma was 
adjusted to the density of 1,21 g/ml by KBr and re-centrifuged to obtain the HDL 
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fraction. All lipoprotein fractions were dialyzed three times against a dialysis 
buffer, and protein concentrations of the lipoproteins were estimated using the 
Bradford protein assay. 
3.4 Lipoprotein Labelling 
Reagents:  
Iodine125 185 MBq (5 mCi, specific activity ~ 17Ci (629GBq)/mg; Hartmann 
Analytic) 
IODO-BEADS iodination reagent kit (Pierce) 
 
Lipoproteins were iodinated with sodium iodide125 (Hartmann Analytic) to 
measure their cellular association. 
Lipoproteins were labeled using the Pierce IODO-BEADS iodination reagent kit. 
For every labeling procedure lipoproteins (500 µg HDL or modified HDL) were 
diluted in PBS to a final concentration of 1 mg/ml. The iodo beads were washed 
in PBS and added to the lipoprotein-PBS solutions. For each labeling procedure 
one iodo bead was used. Finally, the reaction was started by adding 1 mCi 
sodium iodide125. Every sample was incubated at room temperature for 20 
minutes in a radiation protected area. After incubation the reaction was stopped 
by removal of the iodo bead. 
Lipoproteins were separated from free sodium iodide125 by gel chromatography 
using a Pierce D-Salt Dextran Desalting Column. First, the column was 
equilibrated with a fivefold column volume (25 ml) of PBS. The iodinated 
lipoprotein-solution was applied on the gel. Furthermore, the lipoprotein was 
eluted in five steps with PBS, first 750 µl and then with four times 500 µl. The 
fractions were collected and to measure incorporated radioactivity, 1 µl solution 
was measured in a gamma-counter (Cobra II, Packard). In a final step the 
protein concentration was measured using the Bradford protein assay. The 
labeling procedure resulted in a specific activity of 125I HDL of ~ 1000 cpm/ng 
protein. For experiments, lipoproteins were diluted to a specific activity of ~ 300 
cpm/ng protein. 
3.5 High density lipoprotein modification/oxidation 
Reagents:  
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NICK- column (Sephadex G-50, Amersham Biosciences) 
2 mM CuSO4 (Österreichische Apothekerkammer) 
1 mM Ethylenediaminetetraacetic acid, EDTA (Merck) 
5 mM Diethylenetriaminepentaacetic acid, DTPA (Merck) 
Sodium hypochlorite solution, NaOCl; 12% Cl (Roth) 
Potassium cyanate, KCNO (Sigma-Aldrich) 
Phosphate buffer (50x stock solution, pH 7,5) 
1 M Na2 HPO4 (Merck) 
1,5 M NaH2PO4 (Merck) 
pH 7,5 
Wash Buffer 
50 mM TRIS  
1 M Tris (hydroxymethyl) aminomethan, TRIS (Merck) 
1,5 M NaCl 
pH 7,4 
TRIS+-buffer 
TRIS + BSA (2mg/ml) 
 
HDL oxidation with copper modifies the lipid content of HDL particles. HDL was 
modified using different methods using copper (CuSO4), potassium cyanate 
(KCNO) or hypochlorite (HOCl). 
 
HDL modification with CuSO4 
First, HDL at a concentration of 4 mg/ml was separated through a NICK-column 
(Sephadex G-50, Amersham Biosciences) to remove EDTA, which inhibits 
CuSO4 by complex- building (100 µl to column, rinse with 400 µl PBS, eluate 
with 400 µl PBS). Afterwards, HDL was incubated with CuSO4 (final 
concentration 20µM) at 37°C for 4 hours. To stop the reaction of CuSO4 with 
HDL EDTA (final concentration 50 µM) was added. 
 
HDL modification with KCNO/Carbamylation 
HDL at a concentration of 4 mg/ml and 20 mg/ml KCNO in phosphate buffer 
(50mM) was incubated at 37°Cfor 4 hours. After incubation KCNO was removed 
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using a NICK-column (100 µl to column, rinse with 400 µl PBS and then eluate 
with 400 µl PBS). 
 
Measurement of the concentration of sodium hypochlorite (NaOCl) each month 
First, NaOCl was mixed with 50 ml NaOH (10mM). To create dilution series 
(1:2) from 1:200 up to 1:1600 NaOH and NaOCl were mixed in adequate 
amounts. 
The samples were measured photometrically at a wavelength at 292 nm 
(UV/VIS spectrometer Lambda 2, Perkin Elmer). The concentration of HOCl 
was determined using the molar absorption coefficient of HOCl (ε= 350 mol.l-
1.cm-1). 
 
HDL modification with HOCl (Bergt, 2004) 
4 mg/ml of HDL was incubated at 37°C for 1 hour with HOCl (final concentration 
4 mM) to oxidize the protein fraction of HDL. To avoid lipid oxidation DTPA (final 
concentration 100 µM) was added. 
The reaction of HDL with HOCl was stopped using phosphate buffer (0,1 M; pH 
7.5) with a final 1:2 dilution. 
Modified HDL was characterized by measuring lipid peroxidation by TBARS 
assay and by analysis of electrophoretic mobility by gel electrophoresis. 
3.6 TBARS assay (Buege and Aust, 1978) 
Reagents: 
Thiobarbituric acid, TBA (Sigma-Aldrich) 
1 M NaOH (Merck) 
1 mM butylhydroxytoluene, BHT (Merck) 
1 mM EDTA (Merck) 
Principle 
Thiobarbituric acid reactive substances (TBARS) develop during lipid 
peroxidation. TBARS are aledehyde breakdown products from polyunsaturated 
fatty acids. Malondialdehyde (MDA) is the main component of these products. 
One MDA molecule reacts with two molecules of thiobarbituric acid (Fig. 6) to a 
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pink chromogen with absorption at a maximum of 534 nm with a molar 
absorption coefficient of 156 000 mol.l-1.cm-1. 
 
Figure 6. Reaction of Malondialdehyde with Thiobarbituric Acid  
(http://media.wiley.com/CurrentProtocols/NS/ns0717/ns0717-fig-0009-1-full.gif; 
20.07.2010) 
One MDA molecule reacts with two molecules of thiobarbituric acid. The 
resulting product can be measured photometrically at 534 nm. 
 
Thiobarbituric acid 1% (TBA) 
0,5 g TBA was mixed with 2,5 ml NaOH (1 M). Afterwards, 47,5 ml of distilled 
water was added slowly to obtain 1% TBA. TBA can be stored at 4°C for at 
least two weeks. 
For the TBARS assay 0,5 ml TBA (1%), 0,5 ml acetic acid and 0,5 ml of each 
sample were mixed, 10 µl BHT (10 mM) and 10 µl EDTA (1 mM) were added to 
avoid lipid peroxidation during incubation. Afterwards, the samples were 
incubated at 100°C for 45 minutes. After cooling, the samples were measured 
spectrophotometrically at a wavelength of 534 nm and for baseline correction at 
620 nm too (UV/VIS spectrometer Lambda 2, Perkin Elmer). The molar 
concentration of MDA of the samples was calculated (absorption coefficient 156 
000 mol.l-1.cm-1), with the Lambert- Beer’s law.  
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The following formula calculates the molar concentration of MDA: 
 
(E534nm – E620nm) / 156 000 mol.l-1.cm-1 * (volume total /volume sample) 
3.7 Gel Electrophoresis (Ogden and Adams, 1987) 
Reagents: 
Agarose (FMC Bio Products)  
TAE (Tris-acetate-EDTA; 50x stock) 
2 M Tris-Base 
57,1 ml acetic acid 
100 ml EDTA (0,5 M) pH 7,4 
DNA loading dye (6x) (Fermentas) 
Coomassie brilliant blue R 250 (Merck) 
100% acetic acid (ProLab) 
Coomassie stock solution (0,2%): 
0,4 g coomassie blue was dissolved in 80 ml distilled water and 120 ml 
methanol was added. 
Coomassie solution (0,1%): 
50 ml stock solution was filtered and mixed with 10 ml acetic acid and 40 
ml distilled water. 
Destain solution: 
20% Methanol (Fisher Scientific) 
10% acetic acid (Prolab) 
70% distilled water 
 
HDL and modified HDL were separated by gel electrophoresis using 1% 
agarose. To prepare the gel 0,5 g agarose (FMC Bio Products) was mixed with 
50 ml of TAE buffer. The mixture was heated in a microwave oven. The warm 
solution was applied to the casting tray and the comb was inserted. Meanwhile, 
20 µg of HDL or modified HDL were mixed with a 6 x loading dye (1:6). The gel 
was put into the electrophoresis chamber and the chamber was filled with TAE. 
HDL or modified HDL containing the loading dye was load on to the gel. 
Electrophoresis was performed at a constant voltage at 90 V for 2 hours. The 
gel was stained using 0,1% coomassie solution for 15 minutes and destained 
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over night by destain solution containing 20% methanol, 10% acetic acid and 
70% distilled water. 
3.8  Cell Association Experiments 
First, THP-1 cells were differentiated with 160 nM PMA in a 24-well plate at a 
concentration of 5*105 cells/well for 3 days. After differentiation THP-1 
macrophages were grown for 2 days. Additionally, HepG2 cells were plated at a 
concentration of 3*105 cells/well and ldlA7-SRBI cells at a concentration of 1*105 
cells/well in 12-well plates and grown for 2 days.  
On day 2 cells were washed twice with sterile PBS, and reefed with DHG 
medium containing 5% lpds (lipoprotein deficient serum) for ldlA7-SRBI cells, 
MEM + 10% lpds for HepG2 cells and RPMI.  
On the experimental day (day 3) cells were washed twice with PBS (37°C). 
Afterwards, 0,5 ml medium (DHG + 2 mg/ml fatty acid free (faf) BSA) was 
added. To calculate unspecific binding a 40-fold excess of unlabeled lipoprotein 
(HDL) was added to every fourth well. Besides, association experiments were 
also performed using a 20-fold excess of unlabeled differently oxidized or 
modified HDL (Cu-ox. HDL, HOCl-ox. HDL or KCNO-carb. HDL). Afterwards, 
iodinated HDL or modified/oxidized HDL in an amount of 10 µg/ml was added to 
every well and 10 µl aliquots were collected to measure the specific radioactivity 
using a gamma-counter. After having incubated the cells for 3 hours at 37°C, 
the medium was removed and cells were washed twice with 50 mM ice-cold 
TRIS buffer and twice with TRIS + BSA (2 mg/ml). To lyse the cells 1 ml NaOH 
(0,1 M) was added and incubated at room temperature for 1 hour. 300 µl of the 
cell lysates were collected to analyze their radioactivity and counted in a 
gamma counter. Finally, the amount of the proteins in the cell lysates was 
measured by the Bradford protein assay. 
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The following formula calculates specific binding of proteins (ng lipoprotein/mg 
cell protein): 
Counts * (dilution factor/specific activity) 
Total cell protein 
3.9 Cholesterol Efflux Experiments 
Reagents: 
Cholesterol [1,2-3H(N)-] (Perkin Elmer) 
Scintillation cocktail – Ready Safe (Beckman Coulter)  
Bovine Serum Albumin, fatty acid free, faf BSA (2 mg/ml); (PAA Laboratories) 
 
HepG2 cells were seeded at a concentration of 1,5*105 cells/well whereas ldlA7-
SRBI cells were plated at a concentration of 8*104 cells/well. THP-1 cells were 
seeded at a concentration of 5*105 cells/well and differentiated with 160 nM 
PMA for 3 days. All cell lines were grown for 2 days. On day 2 cells were trace-
labeled with 1 µCi of 3H-cholesterol. On the experimental day (day 3) the cells 
were washed twice with PBS (37°C). Afterwards, the cells were equilibrated 
with medium containing faf BSA (2mg/ml) at 37°C for 2 hours. Then the 
supernatant was removed and the cells were incubated at 37°C up to 6 hours 
with HDL (10 µg/ml) or oxidized/modified HDL. Afterwards, the supernatant was 
centrifugated at 1750 RPM and 4°C for 10 minutes (Eppendorf Centrifuge 
5403). 150 or 200 µl of the supernatant was mixed with the scintillation cocktail 
and counted using a beta counter (Tri-Carb 2800 TR; Perkin Elmer). 
Meanwhile, the cells were washed twice with PBS. 500 µl of NaOH (0,1 M) was 
added for cell lysis at room temperature for 1 hour. 200 or 300 µl of the cell 
lysates were mixed with the scintillation cocktail and counted in a beta counter. 
Proteins in the cell lysates were determined using the Bradford assay. 
Efflux is calculated as percentage radioactivity in the media divided by the 
amount of radioactivity in cell lysates and media. Radioactivity was measured 
using a beta counter. 
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The following formula calculates cholesterol efflux: 
% Efflux = 100 x cpm (supernatant) 
cpm (media+lysates) 
3.10 Quantification of Cellular Cholesterol Content by Gas 
Chromatography 
Reagents: 
FOLCH solution: chloroform: methanol (2:1) 
0,1 M NaOH 
 
The cellular lipid content was analyzed by capillary gas chromatography (GC) 
which allows the simultaneous quantification of free cholesterol, cholesteryl 
esters and triglyceride within a single GC run (Lohninger,1990). 
Lipid Extraction 
On day 0 cells were seeded in 6 cm dishes containing 3 ml medium. HepG2 
cells at a concentration of 3*105 cells per dish and ldlA7-SRBI cells at a 
concentration of 5*105 cells per dish. THP-1 cells were seeded at a 
concentration of 5*105 cells per dish and differentiated with 160 nM PMA for 3 
days. The cells were grown for 2 days. On day 2 cells were washed once with 
PBS and reefed with 3 ml MEM (+ 10% lpds) for HepG2, 3 ml DHG (+ 5% lpds) 
for ldlA7-SRBI cells and 3 ml RPMI (+ 5% lpds) for THP-1 cells. On the 
experimental day (day 3) cells were kept in 3 ml DHG (HepG2 and ldlA7-SRBI 
cells) or 3 ml RPMI (THP-1 cells) containing 2 mg/ml faf BSA. Additionally, 10 
µg/ml of native HDL, Cu- oxidized HDL, HOCl- oxidized HDL or KCNO- 
carbamylated HDL was added. Cells were incubated at 37°C for 3 hours. 
Afterwards, the cells were detached with 500 µl trypsin for 5 minutes and 
transferred into glass tubes with 5 ml PBS. After centrifugation at 200 g for 4 
minutes the cell pellets were mixed with 1 ml of distilled water. An aliquot (50 µl) 
of each sample was collected and mixed with 50 µl NaOH (0,1 M) for cell lysis 
for 1 hour and used for protein determination by Bradford. 4 ml of FOLCH 
solution was added to the remaining 950 µl of each sample to start lipid 
extraction. The samples were mixed using a vortex mixer (Model 524, Labinco) 
every 5 minutes for 1 hour and centrifuged at 3000 g for 5 minutes. The 
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supernatant was removed and the remaining phase was concentrated under N2 
atmosphere (Liebisch equipment). The extracts were dried and dissolved in 500 
µl Folch solution and an aliquot was applied to gas liquid chromatography. The 
analyses were carried out on the GC-2010 gas chromatograph (Shimadzu, 
Japan) equipped with a programmed temperature vaporizer injector. Six-meter 
(0.25mm i.d.) – fused silica capillary columns with chemically bound DB-5 were 
used for all analyses. As internal standards tridencanoyl glycerol (for 
cholesterol), cholesteryl myristate (for cholesteryl esters) and trinonadecanoin 
(for triglycerides) were used. The chromatograms were analyzed using GC 
Solutions 2.3 (Shimadzu). Lipid content was normalized for cell protein and 
expressed in µg lipid/mg cell protein. 
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4 Results and Discussion 
High density lipoprotein (HDL) is known to exert cardio-protective effects by 
promoting reverse cholesterol transport (RCT). In RCT HDL removes excess 
cholesterol from peripheral tissues and transports it back to liver for excretion by 
bile (Rader., 2008). 
Dysfunctional HDL is implicated to play a key-role in the pathogenesis of 
atherosclerosis. The underlying pathways remain poorly understood. One 
mechanism involves oxidative modifications of apolipoprotein A-1 (apoA-1), the 
major protein of high density lipoprotein (Shao, 2010). 
This project aims to find out if oxidation of high density lipoprotein alters the 
cholesterol efflux from mammalian cells. Therefore, HDL was modified with 
copper, hypochlorite or potassium cyanate. 
First, we controlled the effectiveness of different HDL modifications by gel 
electrophoresis. Figure 7. shows the characterization of modified particles in 
terms of their electrophoretic mobility compared to native HDL. Modified HDL 
particles migrated more rapidly in the gel than native HDL. These results 
confirmed lipoprotein modifications of the apolipoprotein part. Electrophoretic 
mobility was HOCl-ox. HDL > KCNO- carb. HDL> Cu-ox. HDL > HDL. 
Figure 7. Gel Electrophoresis 
HDL was separated by gel electrophoresis using a 1% agarose gel. 20 µg of 
native HDL, Cu-ox. HDL, HOCl-ox. HDL or KCNO-carb. were used to perform 
gel electrophoresis. Electrophoresis was performed at a constant voltage of 90 
V for 2 hours. 
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Next, the TBARS assay was applied to estimate the extent of lipid oxidation. 
 
 Native HDL Cu-ox. HDL HOCL-
ox.HDL 
KCNO-carb. 
HDL 
µM MDA 4,6 ± 0,1 10,8 ± 1,3 2,5 ± 2,7 1,4 ± 1,1 
 
The data represent mean ± SD of five independent measurements. 
The results are expressed in µg MDA (Malondialdehyde) developing in the 
samples during incubation time of one hour. 
 
HDL oxidation by copper strongly induced lipid peroxidation. This resulted in an 
increase of malondialdehyde in copper oxidized HDL. TBARS formation in 
copper oxidized HDL was elevated 2-fold compared to native HDL(4,6 ± 1 vs. 
10,8 ± 1,3). 
In contrast, native HDL, KCNO- carbamylated HDL and HOCl- modified HDL 
showed no increase in TBARS formation.  
To summarize, copper induced oxidation modifies the lipid content of HDL as 
well as its apolipoproteins, whereas hypochlorite or potassium cyanate seems 
to modify only the apolipoprotein content of the HDL particles. 
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4.1 Cholesterol Efflux in mammalian Cells 
To determine cholesterol efflux from mammalian cells efflux experiments in 
HepG2 and ldlA7-SRBI cells up to four hours and in human THP-1 
macrophages up to six hours were performed.  
HepG2 cells were used as a liver model, the ldlA7-SRBI cell line as a model 
over-expressing the HDL receptor SR-BI and human THP-1 macrophages as a 
more physiological model for macrophages involved in all stages of 
atherosclerosis (Boyle, 2005). 
4.1.1 Cholesterol Efflux in HepG2 cells 
In HepG2 cells, cholesterol efflux to copper-oxidized HDL (Cu - ox. HDL), HDL 
modified with hypochlorite (HOCl) or HDL carbamylated by potassium cyanate 
(KCNO-carb.HDL) decreased significantly compared to native HDL. Cholesterol 
efflux was reduced compared to native HDL in a time dependent manner up to 
4 hours. 
It is described that hepatocytes show high levels of ABCA1 expression to 
promote apoA-1 mediated cholesterol efflux. In ABCA1-/- mice, hepatocytes 
showed a decrease in cholesterol efflux to HDL containing apoA-1. However, 
nascent apoA-1 particles are the preferred substrate for ABCA1 (Sahoo, 2004). 
Malondialdehyde developed from lipid peroxidation impairs the ability of apoA-1 
to interfere with ABCA1 which results in decreased cholesterol efflux (Shao, 
2010).  
Bergt et al. (2004) showed that HDL exposed to HOCl was less able to remove 
cholesterol from cultured cells. The ABCA1 pathway may also be impaired by 
dysfunctional HDL (Bergt, 2004; Shao, 2010). 
These findings, together with our results, indicate that all modifications tested 
alter efflux to HDL. Consequently, different receptors including SR-BI and 
ABCG1 (which are expressed in HepG2 cells) might be involved in the effects 
observed. 
Taken together, cholesterol efflux decreased ∼ 70% within four hours using 
HOCl-ox. HDL or Cu-ox. HDL in HepG2 cells. KCNO-carb. HDL exhibited a 
reduction of cholesterol efflux of ∼ 60% after 4 hours of incubation. 
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Figure 8. Cholesterol Efflux in HepG2 cells 
HepG2 cells were seeded into 24-well plates at a density of 1,5*105 cells/well. 
Cells were grown for 2 days followed by trace-labeling with 1 µCi of 3H-
cholesterol. On day 3 cells were washed twice with PBS and equilibrated with 
MEM containing faf-BSA (2 mg/ml) at 37°C for 2 hours. After 2 hours the 
supernatant was removed and efflux at 37°C up to 4 hours was started. 
Therefore cells were incubated with 10 µg/ml of HDL, Cu-ox. HDL, HOCl-
ox.HDL or KCNO-carb.HDL. Afterwards, 150 or 200 µl of the supernatant were 
mixed with the scintillation cocktail and counted in a beta counter  
 
Each data point represents mean of triplicates of two independent experiments. 
The results are expressed as % of initial loading (100%). Statistical significance 
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was analyzed using an unpaired t-test for all experiments. P < 0,001 (***); r2 > 
0,97 
4.1.2 Cholesterol Efflux in ldlA7-SRBI cells 
In the ldlA7-SRBI cell line copper-induced modification of HDL decreased 
cholesterol efflux significantly up to 4 hours. The data points show a linear 
regression of r2 > 0,97, this may indicate further reduction of cholesterol efflux 
beyond an incubation time of 4 hours (Fig. 10). 
Also HDL modified by hypochlorite showed a decrease of cholesterol efflux, 
especially after 4 hours, efflux dropped to 75% compared to native HDL, which 
serves as a control. It is well established that myeloperoxidase (MPO) is 
involved in vivo in generating oxidants which are associated risk factors in 
atherogenesis. Hypochlorite modified HDL is widely used as a model for 
myeloperoxidase products occurring in atherosclerotic lesions (Marsche, 2008). 
All the more it was interesting to estimate the influence of HOCl-modified HDL 
on cholesterol efflux. 
In ldlA7-SRBI cells there was also a trend to decrease efflux for KCNO-
carb.HDL, although these effects were not pronounced and did not reach 
statistical significance. 
SR-BI is reported to serve as a ligand for oxidized HDL as well as HDL 
(Marsche, 2002).  
Especially, Cu-oxidized HDL resulted in a ∼ 50% reduction of cholesterol efflux 
compared to native HDL. 
Figure 9. Influence of modified HDL on cholesterol efflux from ldlA7-SRBI 
cells. 
Cells were grown and treated as described in Figure 9 (HepG2). ldlA7-SRBI 
cells were plated in 24-well plates at a concentration of 8*104 cells/well. 
Efflux was calculated as percentage radioactivity in the media divided by the 
amount of radioactivity from cell lysates and media.100% represents the initial 
loading of the cells. 
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Each data point represents triplicates of one representative experiment. The 
results are expressed in % of initial loading of the cells. 
p < 0,05(*); p < 0,01 (**); p < 0,001 (***); linear regression:  r2 > 0,97 
4.1.3 Cholesterol Efflux in THP-1 Macrophages 
Macrophages are involved in all stages in the pathogenesis of atherosclerosis 
(Corrado, 2010). Nevertheless, THP-1 macrophages showed almost no 
response to different modified HDL. After 6 hours incubation with copper-
oxidized HDL (Cu - ox. HDL), HDL modified with hypochlorite (HOCl) or HDL 
carbamylated by potassium cyanate (KCNO-carb.HDL) we determined a 
tendency of reduced cholesterol efflux. 
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Figure 10. Cholesterol Efflux to modified HDL in THP-1 macrophages 
Human THP-1 monocytes were differentiated into macrophages over 3 days 
with 160 nM PMA at a concentration of 5*105 cells/well. After differentiation cells 
were depleted with 5% lpds and trace-labeled using 1 µCi of 3H-cholesterol as 
described in Figure 9 (HepG2). To analyze cholesterol efflux cells were 
incubated with 10 µg/ml of native HDL or HDL modified by copper, hypochlorite 
or potassium cyanate. 
 
Each data point represents mean ± SD of triplicates of three independent 
experiments. The results are expressed as % of initial loading. Statistical 
significance was analyzed using an unpaired t-test for all experiments. Linear 
regression r2 > 0,98 
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4.2 Gas Chromatography Analysis of Cellular Cholesterol Content 
We wanted to confirm, whether decrease in cholesterol efflux to modified HDL 
results in increased cellular cholesterol levels. To quantify cellular cholesterol 
content we performed gas – liquid chromatography in HepG2 and ldlA7-SRBI 
cells. 
4.2.1 Cellular Cholesterol Content in HepG2 cells 
 control HDL Cu-ox. HDL HOCl-ox. HDL KCNO-
carb. HDL 
CE 26,8 ± 8,0 23,7 ± 8,5 30,2 ± 20,9 33,1 ± 19,4 40,2 ± 35,4 
FC 130,7 ± 18,2 108,6 ± 13,4 119,3 ± 38,9 145,9 ± 46,6 146,5 ± 58,4 
TC 157,5 ± 25,7 132,3 ± 20,1 149,5 ± 58,9 179,0 ± 66,6 186,7 ± 93,5 
 
The results are expressed as µg of CE, FC or TC/mg cell protein. The data 
represent mean ± SD of four independent experiments. 
 
First, we estimated free cholesterol (FC), cholesteryl esters (CE) and total 
cholesterol (TC) in HepG2 cells after 3 hour incubation with HDL or differently 
modified HDL (10 µg/ml). In liver cells CE are stored in a high amount (Maxfield, 
2002). Our results show that HepG2 cells had a higher content of CE than 
ldlA7-SRBI cells. For example, incubation with native HDL results in a CE 
content of ∼ 24 µg /mg protein in HepG 2 cells (Fig. 12); in contrast in ldlA7-
SRBI cells (Fig. 13) only ∼ 1,2 µg CE/ mg protein were detectable. 
In HepG2 cells, neither, incubation with Cu-oxidized HDL or HOCl-oxidized 
HDL, nor, KCNO-carb. HDL showed a significant change in CE, FC and TC 
content. Nevertheless, differently modified HDLs showed an increase of cellular 
cholesterol content compared to native HDL. However, intra-experimental 
deviations were too large to reach statistical significance. This leads to the 
assumption, that modification of HDL induced by HOCl or KCNO may tend to 
result in an increase of CE, FC and TC. 
Taken together, these data confirm our findings for efflux studies: modified HDL 
cause reduced cholesterol efflux and therefore cellular lipid contents were 
increased. 
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4.2.2 Cellular Cholesterol Content in ldlA7-SRBI cells 
 Control HDL Cu-ox. 
HDL 
HOCl-ox. 
HDL 
KCNO-
carb. HDL 
CE 0,3 ± 0,3 1,4 ± 0,3 1,4 ± 0,3 2,6 ± 0,5 2,1 ± 0,3 
FC 40,0 ± 3,4 42,8 ± 2,3 46,4 ± 1,6 47,0 ± 0,6 46,7 ± 1,2 
TC 40,3 ± 3,5 44,3 ± 4,0 47,8 ± 1,3 49,7 ± 1,0 48,9 ± 1,1 
 
The results are expressed as µg of CE, FC or TC/mg cell protein. The data 
represent mean ± SD of triplicates of four independent experiments.  
 
In the ldlA7 SR-BI cell line we observed a significant increase of CE derived 
from HOCl-oxidized HDL compared to native HDL. Modification of HDL by HOCl 
significantly increased CE within cells from 1,4 to 2,6 µg/mg cell protein; in other 
words CE increased about ∼ 50% compared to native HDL. KCNO-induced 
carbamylation of HDL, similarly to HOCl-ox. HDL, showed a 50% increase from 
1,4 to 2,1 µg/mg cell protein, whereas copper induced oxidation of HDL showed 
no significant increase compared to native HDL.  
Free cholesterol was estimated in an average amount of 40 µg/mg protein (after 
incubation with or without HDL). In analogy to cholesteryl esters (CE), free 
cholesterol (FC) significantly increased due to modifications of HDL by 
hypochlorite or KCNO, again almost no difference to native HDL came up by 
incubation of ldlA7 cells with copper-oxidized HDL. FC content just increased 
slightly from ∼ 40 to ∼ 47 µg/ mg cell protein. Furthermore, we estimated total 
cholesterol (TC) and observed no significant change in the total cholesterol 
content by incubation with modified HDL compared to native HDL in ldlA7-SRBI 
cells. These data confirm in some extent our findings from the efflux studies: 
HOCl-ox. HDL and KCNO-carb. HDL has reduced efflux and therefore lipid 
content was increased by these modifications in ldlA7-SRBI cells. Although, Cu-
ox. HDL reduced cholesterol efflux about ~ 50% compared to native HDL, there 
was almost no increase of cellular lipids induced by Cu-ox. HDL. 
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4.3 Cell Association of [125I]-HDL and [125I]-modified HDL  
To analyze if modifications of HDL result in different cell binding and uptake we 
performed association and competition experiments in HepG2, ldlA7-SRBI cells 
and THP-1 macrophages. 
4.3.1 Cell Association in HepG2 cells 
 Total Binding Specific Binding 
(20x lipoprotein) 
Specific Binding 
(40x HDL) 
HDL 147,3  79,0  29,0  
HOCl-ox. HDL 97,0  38,5  41,0  
Cu-ox. HDL 119,0  63,0 35,5  
KCNO-carb. HDL 146,3  90,0  63,0 
 
The results are expressed as ng lipoprotein/mg cell protein. The data represent 
means of triplicates of one representative experiment.  
 
In HepG2 cells no effect of native HDL (40-fold excess) on 125I HDL or 125I HDL 
modified by Cu2+ or HOCl in regard to specific binding was observed. 125I 
KCNO-carbamylated HDL showed a slightly increase in specific binding 
competed by native HDL (40-fold excess). We observed nearly the same results 
on specific binding of 125I HDL or 125I modified HDL competed by HDL, Cu-ox. 
HDL, HOCL-ox. HDL or KCNO-carb. HDL (20-fold excess of each).  
 
Compared to ldlA7 SR-BI over-expression cells HDL cell association in HepG2 
cells was reduced to ∼ 80%. HepG2 cells contain few SR-BI, known as a ligand 
for HDL, compared to ldlA7-SRBI cells. This could be the reason for reduced 
HDL cell association of HDL.  
4.3.2 Cell Association in ldlA7-SRBI cells 
 Total Binding Specific Binding 
(20x lipoprotein) 
Specific Binding 
(40x HDL) 
HDL 263,5  107,3  86,0  
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HOCl-ox. HDL 225,5  142,5  162,0  
Cu-ox. HDL 346,2  191,7  182,7  
KCNO-carb. HDL 124 61,0  44,0 
 
The data represent means of triplicates of two independent experiments. The 
results are expressed as ng lipoprotein/mg cell protein. 
 
Specific cell association, termed as competition of 125I HDL or 125I modified HDL 
with 20x excess of unlabeled native or modified HDL, was nearly the same as 
competition by native HDL in ldlA7-SRBI cells. Only KCNO-carbamylated HDL 
competed well with native HDL in a 40-fold excess. Nevertheless, the results 
clearly demonstrate an increase of cell association induced by Cu2+ oxidized 
HDL compared to native HDL by ∼ 31%. SR-BI, is assumed to be a multiligand 
receptor to bind oxidized HDL as well as native HDL, LDL or oxidized HDL and 
mediated selective uptake of CE. This may indicate a high affinity of modified 
HDL to SR-BI promoting selective CE uptake. Our results may indicate a high 
affinity of SR-BI to oxidized HDL.  
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4.3.3 Cell Association in THP-1 Macrophages 
 Total Binding Specific Binding 
(20x lipoprotein) 
Specific Binding 
(40x HDL) 
HDL 118,0  68,0  7 
HOCl-ox. HDL 66,7  49,0  31,5  
Cu-ox. HDL 259,0  142,5  209,3  
KCNO-carb. HDL 72,3  33,5  61,5  
 
The results are expressed as ng lipoprotein/mg cell protein. The data represent 
means of triplicates of two independent experiments. 
 
THP-1 macrophages revealed a 2-fold increase of Cu-ox. HDL cell association 
compared to HDL cell association. Nevertheless, Cu-ox. HDL was not well 
competed by native HDL. This was also reported by Nakajima et al. (2000).  
Taken together, these data indicate that all tested modifications of HDL result in 
a different receptor affinity compared to native HDL. 
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5 Conclusion 
Dysfunctional high density lipoprotein (HDL), mainly generated through 
modifications of the major protein of HDL, apoA-1, is assumed to be implicated 
in the pathogenesis of atherosclerosis (Shao, 2010). It is thought to alter 
reverse cholesterol transport (RCT), an important process in the removal of 
excess cholesterol from cells for transport to the liver for disposal into bile. 
Furthermore, dysfunctional HDL is supposed to reduce cholesterol efflux from 
cells (Marsche, 2002).  
We detected a cell-specific response to modified HDL in tissue culture cells. 
Modification of HDL by copper, hypochlorite or potassium cyanate strongly 
induced a decrease of cholesterol efflux capacities in HepG2 cells. 
In ldlA7 SR-BI cells modifications of HDL by copper and hypochlorite resulted in 
a time-dependent decrease of cholesterol efflux. THP-1 macrophages showed 
almost no response to differently modified HDLs. 
The alterations in cholesterol efflux capacities resulted in increased lipid content 
in HepG2 and ldlA7-SRBI cells. We assumed that these effects were in part the 
results of different receptor binding as a consequence of HDL modifications. 
These effects differed for the single modifications. 
 
Taken together, we showed altered cholesterol efflux in tissue culture cell lines. 
Moreover, these effects might also modulate RCT in vivo and might be a 
mechanism for the induced atherogenity of modified HDLs. 
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6 Abstract 
The cardioprotective effects of high density lipoprotein (HDL) are generally 
attributed to reverse cholesterol transport, a process to remove excess 
cholesterol from artery wall macrophages to liver for excretion into bile. 
It has been proposed that HDL looses its cardioprotective ability through 
oxidative modifications by reactive oxygen species or myeloperoxidase, both of 
them are present in atherosclerotic lesions in vivo. One potential mechanism 
generating dysfunctional HDL involves oxidative modifications of apoA-1, the 
major protein of HDL.  
This project aimed to characterize, whether oxidation of HDL exhibits alterations 
on lipid transfer from HDL to cells and vice versa. Therefore, HDL was oxidized 
or modified using copper, potassium cyanate or hypochlorite. The resulting 
oxidation products were analyzed on regard lipid oxidation (TBARS assay) and 
to electrophoretic mobility. We have analyzed the impact of modified HDL on 
cholesterol efflux in human THP-1 macrophages, human hepato-carcinoma 
cells (HepG2) and in Chinese hamster ovarian (CHO) cells over-expressing 
scavenger receptor class B type 1 (ldlA7-SRBI). HOCl- and Cu2+- induced 
modification of HDL resulted in a significant, time–dependent decrease in 3H-
Cholesterol efflux from HepG2 and ldlA7-SRBI cells, whereas THP-1 
macrophages exhibited almost no response to modified HDL. Decreased efflux 
resulted in elevated free cholesterol (FC), cholesteryl esters (CE) and total 
cholesterol (TC) levels, as measured by gas chromatography. Furthermore, we 
attempted to analyze, whether these effects were due to altered receptor 
interaction as a result of the modifications. 
Taken together we found that modified HDL negatively affects cholesterol efflux 
in tissue culture cells. The generation of modified or oxidized HDL in vivo might 
therefore be regarded as possibly atherogenic. 
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7 Zusammenfassung 
Viele Studien bestätigen die atheroprotektive Wirkung von high density 
lipoprotein (HDL). Diese wird der Rolle von HDL im „Reversen Cholesterin 
Transport“ (RCT) zugeschrieben. Dabei wird überschüssiges Cholesterin aus 
peripheren Zellen von HDL zur Leber transportiert und über die Galle 
ausgeschieden. 
Es wird vermutet, dass HDL seine schützende Wirkung verliert, wenn es durch 
freie Radikale oder durch Enzyme mit oxidierender Wirkung, die bei 
entzündlichen Erkrankungen- wie auch im Fall der Atherosklerose- im Körper 
vermehrt freigesetzt werden, modifiziert wird.  
Thema dieser Diplomarbeit war zu erforschen, inwiefern sich Modifikation/ 
Oxidation von HDL auf den Cholesterinefflux in Zellkultur auswirkt. Für dieses 
Projekt wurden folgende Zelllinien verwendet: humane Lebertumorzellen 
(HepG2), Zellen, die den HDL-Rezeptor SR-BI überexprimieren (ldlA7-SRBI) 
und humane THP-1 Makrophagen. HDL wurde einerseits durch Oxidation 
mittels Kupfer und Hyperchlorit, andererseits mittels Kaliumcyanat, modifiziert. 
Besonders in den Zelllinien HepG2 und ldlA7-SRBI wurde der Efflux von 
Cholesterin aus der Zelle bis zu 70% verringert. THP-1 Makrophagen zeigten in 
Bezug auf modifiziertes HDL kaum eine Änderung des Cholesterinefflux.  
Mittels Gaschromatographie wurde der Gehalt an Cholesterin nach Behandlung 
mit nativem HDL und modifiziertem HDL analysiert. Die HDL Modifizierung 
führte  zu einem erhöhten Gehalt an zellulärem Gesamtcholesterin (TC), freiem 
Cholesterin (FC) und Cholesterinestern (CE). Abschließend wurde untersucht, 
ob die Modifizierung zu einer veränderten Affinität zu zellulären Rezeptoren 
führt. 
Zusammengefasst kann gesagt werden, dass Modifizierungen von HDL den 
Cholesterinefflux senken und somit modifiziertes HDL als atherogen angesehen 
werden muß. 
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